Retina

Researchers discovered that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.

According to researchers, factors that were associated with all type of visual impairment included older age, lower education level, and lower income were associated with all types of visual impairment.

Diabetic retinopathy is the leading cause of blindness in American adults, and a team of researchers believes the source of this damage may lie in the belly — mainly a leaky small intestine. A novel treatment can possibly prevent or reverse this damage.

Ultra-widefield imaging may be a promising technology for assessing larger areas of the retinal vasculature to uncover retinal changes in Alzheimer’s disease, according to investigators.

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report.

The researchers conducted a retrospective chart review of patients with typical exudative AMD that had been treated with anti-VEGF therapy injections.

FT-001 is administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.

The delivery of VivaVision's molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.

A team of researchers from the University of Wisconsin–Madison developed a way to grow organized clusters of cells, called organoids, that resemble the retina, the light-sensitive tissue at the back of the eye.

Ocular involvement in IBD is a rare extraintestinal manifestation, but may be critical because of its potential sight-threatening complications if not treated promptly and accurately, according to researchers.

The research team reported a few differences in patients that included a decreased mean vessel density at the deep vascular complex of the macula, a decreased mean subfoveal choroidal thickness, and an increase in the size of the foveal avascular zone.

Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.

According to a news release, Opus will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.

According to investigators, the study demonstrated that by restoring the function of ADAM10, a major shedding protein, it was possible in preclinical models to control the abnormal formation of blood vessels, offering an attractive therapeutic target to treat DR.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

Resection techniques for choroidal tumours are based on modern vitreoretinal surgical techniques, which allow for the treatment of more challenging cases.

The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.

According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.

Retinopathy of prematurity is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.

Findings may help pediatricians and ophthalmologists to determine the appropriate timing of examinations and treatment.

Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Pegcetacoplan is the only GA treatment to demonstrate increased effects over 24 months across a broad patient population.